Drug Development Pipeline
Azithromycin is an oral antibiotic with anti-inflammatory properties.
A Phase 3 trial showed CF patients with chronic Pseudomonas aeruginosa who took azithromycin experienced improved lung function and weight gain and decreased hospitalization rate. A follow-up trial showed that azithromycin decreased exacerbations in younger people with CF not infected with P. aeruginosa. Cystic Fibrosis Foundation Therapeutics (CFFT) is supporting a trial in infants in Australia.
The program is fully funded through the Cystic Fibrosis Foundation and is being conducted within the Therapeutics Development Network.
Recent Azithromycin Studies
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.Learn More